Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities. Meeting Abstract (Web of Science)

Industry Collaboration International Collaboration

cited authors

  • Tsimberidou, Apostolia Maria; Verschraegen, Claire F.; Weise, Amy M.; Sarantopoulos, John; Lopes, Gilberto; Nemunaitis, John J.; Hicking, Christine; Shaw, Jamie; Kaleta, Remigiusz; Kurzrock, Razelle

publication date

  • May 20, 2018

webpage

published in

category

volume

  • 36

issue

  • 15